Clinical Trials in Phoenix

Showing 8181-8200 of 16,646 trials

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

NCT02852967

This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Chronic Plaque Psoriasis

Kadmon Corporation, LLC110 participantsStarted Sep 2016

Phoenix, Arizona, United States • Irvine, California, United States • Los Angeles, California, United States +11 more locations

COMPLETEDPhase 3< 1 mile

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299

This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.

PsoriasisPsoriatic Arthritis

Amgen250 participantsStarted Oct 2012

Phoenix, Arizona, United States • Bakersfield, California, United States • Irvine, California, United States +79 more locations

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Find Trials by Condition in Phoenix

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Remote Self-training Program for Patients With Postural Orthostatic Tachycardia Syndrome

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

HTX-011 Administration Study in Planned Caesarean Section Procedure

Adaptive COVID-19 Treatment Trial (ACTT)

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

Study of FCN-437c in Patients With Advanced Solid Tumors

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

Fetal Pulse Oximetry Trial (FOX)

Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children